Full Text
PSY22 ANALYSING THE BENEFITS AND COST SAVING OF ORAL VERSUS IV FLUDARABINE FOR MANAGEMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

Abstract

Authors

P.L. Zinzani J.M. Connors A.D. Knight A.M. Crowe R. Jones B. Tucker

Back to Volume 14, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×